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Introduction: Since the beginning of the epidemic, human immunodeficiency virus (HIV) has taken 
more than 36 million lives.
Objective: To determine the antiretroviral drug prescription patterns in a population of individuals with 
HIV infection in Colombia.
Materials and methods: Cross-sectional study analyzing the profiles of patients treated with antiretroviral 
drugs between April 1st and September 30th, 2015. The sociodemographic, pharmacological, and 
comorbidity variables were identified. Individuals with a positive diagnosis of HIV of all ages and both 
genders were included.
Results: We found 641 patients with a mean age of 39.0±17 years who were predominantly male 
(60.2%). The most used medications were lamivudine-zidovudine (51.6%), lopinavir-ritonavir (36%) 
and efavirenz (24.5%). The combination of lamivudine-zidovudine plus lopinavir-ritonavir was the most 
prescribed regimen (29.5%), but a total of 80 different regimens was identified. Being an adult between 
the ages of 45-64 years (OR=2.25; 95%CI 1.367-3.713) was associated with a greater probability 
of receiving 4 or more antiretrovirals. A total of 267 (41.6%) patients used at least one comedication 
(range: 1-18 drugs), especially anti-ulcer (57.3%), lipid-lowering (28.8%) and anti-hypertensive (28.5%) 
drugs.
Conclusions: Patients undergoing antiretroviral treatment are receiving medications with elevated 
intrinsic values at the recommended doses and present comorbidities associated with chronic age-
related conditions. However, these patients receive a great variety of regimens that are not included in 
the clinical practice guidelines.
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prescriptions; pharmacoepidemiology.
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Perfil de utilización de antirretrovirales en Colombia
Introducción. La infección por HIV es una pandemia que actualmente se controla con el tratamiento 
farmacológico, el cual, además, prolonga la expectativa de vida del paciente.
Objetivo. Determinar los patrones de prescripción de fármacos antirretrovirales en una población 
de personas afiliadas al régimen contributivo del Sistema General de Seguridad Social en Salud de 
Colombia, durante el 2015.
Materiales y métodos. Se hizo un estudio de corte transversal para analizar la formulación de 
fármacos antirretrovirales en pacientes tratados con estos entre el 1° de abril y el 30 septiembre del 
2015. Se determinaron las variables sociodemográficas, farmacológicas y las comorbilidades, y el 
análisis estadístico se hizo mediante SPSS™, versión 23.0.
Resultados. Se hallaron 641 pacientes, la mayoría (60,2 %) hombres, con una edad media de 
39,0±17 años. Los medicamentos más empleados fueron lamivudina-zidovudina (51,6 %), lopinavir-
ritonavir (36 %) y efavirenz (24,5 %). La asociación lamivudina-zidovudina más lopinavir-ritonavir fue el 
esquema más prescrito (29,5 %), pero se encontraron 80 esquemas diferentes. El ser un adulto entre 
45 y 64 años (odds ratio=2,25; IC95% 1,367-3,713; p=0,001) se asoció con una mayor probabilidad 
de recibir cuatro o más antirretrovirales. Del total de pacientes, 267 (41,6 %) recibían más de un 
medicamento simultáneamente (rango: 1-18 fármacos), especialmente fármacos contra las úlceras 
(57,3 %), hipolipemiantes (28,8 %) y antihipertensivos (28,5 %).
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Conclusiones. Los pacientes en tratamiento antirretroviral están recibiendo medicamentos de elevado 
valor intrínseco en las dosis recomendadas, y presentan las mismas comorbilidades asociadas con las 
condiciones crónicas relacionadas con la edad. Además, reciben una gran variedad de esquemas que 
no se encuentran incluidos en las guías de práctica clínica.
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prescripciones de medicamentos; farmacoepidemiología.
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Since the beginning of the epidemic, human 
immunodeficiency virus (HIV) has taken more 
than 36 million lives (1,2). Towards the end of 
2012, approximately 35.3 million people were 
estimated to be living with HIV (3). This increase 
in prevalence has largely been a consequence of 
the transition of HIV from a highly lethal disease 
to a chronic and treatable condition (4). This 
transition has mostly been the product of the use 
and expansion of antiretroviral therapy (ART) 
worldwide. Between 1995 and 2010, ART use 
avoided an estimated 5.2 million deaths related to 
acquired immunodeficiency syndrome (AIDS) in 
middle- and low-income countries; moreover, ART 
resulted in a 28% reduction in deaths between 
2006 and 2012 (3,5).
ART has been transformed, and multiple drugs 
have been added to the therapeutic arsenal (6). 
Towards the end of the 1990s, the course of the 
HIV epidemic changed drastically due to the 
approval of three protease inhibitors (PIs) for HIV 
and the use of highly active antiretroviral treatment 
(HAART). The combined therapy led to a rapid 
reduction in viral RNA, improvement of immune 
functions, regression of hard-to-treat opportunistic 
infections and a reduction in mortality (7).
In 2014, 28 antiretroviral drugs belonging to 
six different classes of action mechanisms 
were approved for use in the United States (7). 
Currently, the recommended ART regimens 
are less toxic, more effective, have a lower pill 
burden and are dosed with a lower frequency 
than the original regimens based on nucleoside 
reverse transcriptase inhibitors (NRTIs) (8). A 
standard treatment combines two NRTIs with a 
non-nucleoside reverse transcriptase inhibitor 
(NNRTI), a PI or an integrase inhibitor (9). In low- 
and medium-income countries, the World Health 
Organization (WHO) recommends the use of ART 
with standardized first and second line regimens 
of two NRTIs plus one PI enhanced with ritonavir. 
In these countries, monitoring the viral load is a 
cost-effective tool for evaluating treatment, but 
resistance tests are not always available (10).
Colombia has a health system that provides 
universal coverage through a paid regime and a 
second system subsidized by the state. Access 
to ART for patients diagnosed with HIV/AIDS 
is covered by the benefits plan contained in a 
manual of medications called the Obligatory Health 
Plan (Plan Obligatorio de Salud, POS), which is 
updated and includes the majority of the drugs of 
the group (11). However, the low accessibility to 
resistance tests for HIV and scarce adherence to 
clinical practice guidelines have given rise to the 
implementation of diverse treatment protocols for 
HIV/AIDS. Some of these protocols are adopted 
empirically and are not based on recommendations 
from scientific evidence (12). This study describes 
the antiretroviral use patterns in the Colombian 
population and identifies the main associated 
variables with the aim of improving knowledge on 
the pharmacological management of this disease 
and promoting the rational use of medications in 
the context of public health.
Materials and methods
A cross-sectional study was conducted to 
investigate the use of antiretroviral drugs in a 
sample of individuals affiliated with the contributive 
or paid scheme of the Health System of Colombia 
in 11 insurance companies called Health Promoting 
Entities (Entidades Promotoras de Salud, EPS).
The patient profiles were analyzed between April 
1st and September 30th, 2015, in all Colombian 
cities that had reliable databases. Individuals with 
a positive diagnosis of HIV of all ages and both 
genders who were treated in the different programs 
for the control of this disease in the EPSs were 
included.
The database was designed and validated by a 
pharmacologist who reviewed patient data one 
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by one to guarantee its quality. We obtained 
the following groups of variables based on the 
information on the consumption of medications 
collected systematically and without interruption by 
the company (Audifarma, S.A.) that delivered the 
medications to approximately 6.5 million affiliates 
(corresponding to 13.8% of the country):
1. Demographic variables: age, gender, and city.
2. Antiretroviral medications prescribed and their 
respective doses: NRTIs (zidovudine, lamivudine, 
and didanosine), NNRTIs (efavirenz and 
nevirapine), PIs (lopinavir-ritonavir and atazanavir), 
fusion inhibitors (enfuvirtide), integrase inhibitors 
(raltegravir, elvitegravir, and dolutegravir) and 
coreceptor CCR5 antagonists (maraviroc). The 
dose used was established as a technical unit of 
measurement as the defined daily dose (DDD) per 
1,000 inhabitants per day.
3. Regarding the type of combinations used, we 
identified all possible combinations of antiretroviral 
drugs used and we investigated whether these 
regimens were based on combinations established 
by the clinical practice guidelines for a given 
morbidity.
4. We determined the comorbidities and co 
medications patients received. To this end, 
medication was accepted as a substitute indi- 
cator of a disease as follows: a) Anti-ulcer drugs/
peptic acid disease; b) anti-diabetic drugs/
diabetes mellitus; c) anti-depressants/depression 
or neuropathic pain; d) anxiolytics and hypnotics/
anxiety or sleep disorder; e) lipidlowering drugs/
dyslipidemia; f) thyroid hormone/hypothyroidism; 
g) nitrovasodilators/ischemic heart disease; h) 
antihypertensive drugs and diuretics/arterial 
hypertension; i) mood stabilizers/affective bipolar 
disorder; j) antipsychotic drugs/schizophrenia 
or psychosis; k) antiepileptic drugs/epilepsy 
or neuropathic pain; l) antiarrhythmia drugs/
cardiac arrhythmias; m) antituberculosis drugs/
tuberculosis; n) antivirals/hepatitis B, C, herpes 
virus or cytomegalovirus depending on the 
case; o) antifungals/mycosis; p) trimethoprim/
sulfamethoxazole/pneumocystosis; q) anticoagu 
lants/atrial fibrillation; r) antiplatelet agents/cardio 
vascular prevention; s) inotropes/heart failure, 
and t) hormonal birth control.
The study protocol was approved by the Bioethics 
Committee of the Universidad Tecnológica de 
Pereira and respected the principles of patient 
confidentiality according to the Declaration of 
Helsinki.
The statistical program SPSS™ 23 for Windows 
(Armonk, New York, USA) was used for data 
analysis. Student’s t-test or analysis of variance 
(ANOVA) was used for the comparison of 
quantitative variables and the chi-square test 
for the categorical variables. Binary logistical 
regression models were applied considering the 
use of comedication and the need to use four or 
more antiretrovirals as the dependent variables. 
A level of statistical significance of p<0.05 was 
established.
Results
A total of 1,476 patients were undergoing anti re- 
troviral treatment. However, fewer than three of 
these medications were being dispensed to 835 
patients; these cases were discarded, because the 
medications were delivered by another provider and 
there was no assurance that the patients received 
the complete scheme, resulting in the inclusion of 
641 cases in the analysis.
The 641 patients were from 28 different cities in the 
country and were treated by 18 health institutions. 
The distribution by gender showed that 386 of the 
patients (60.2%) were male, and 255 (39.8%) were 
female, with a male:female ratio of 1.5:1.0 and a 
mean age of 39.0 ± 17 years (range: 1-77 years). 
Figure 1 shows the distribution of this group of 
patients by age and gender.
Table 1 summarizes the prescription patterns of 
the ten most frequently used drugs, which are 
part of the list of essential medicines with which 
the program to control HIV/AIDS in Colombia is 
managed. These drugs represent 78.5% of the 
medications prescribed. 
When considering the drugs by pharmacological 
group, the most prescribed agents were (in order) 
NRTIs (91.4%), PIs (59.4%), NNRTIs (44.1%), 
integrase inhibitors (23.2%), co-receptor CCR5 
antagonists (2.2%), and fusion inhibitors (0.2%). 
The same table presents the DDD indicator, 
which shows that the majority of the drugs were 
being used in adequate doses in relation to those 
determined internationally and that ritonavir was 
used more as an enhancer of the PIs than as an 
antiretroviral.
Antiretroviral combinations
A total of 538 patients (83.9%) were receiving three 
antiretrovirals, and 103 (16.1%) were prescribed a 
combination of four or more drugs. There were 74 
cases (11.5%) receiving four, 22 (3.4%) receiving 
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Table 1. Patterns of prescription of the most frequently used antiretrovirals in Colombia and relation between the mean dosage and 
the defined daily dose (DDD)
Figure 1. Distribution by age and gender of the 641 patients 
undergoing antiretroviral treatment in Colombia, 2015
Table 2. Combinations of antiretrovirals most frequently used 
in Colombia
Prescriptions/
patients
Prescribed dose 
(mg/day)
nDDDa
Sex 
ratio
Age (mean, years)
Drug n  (%) Mean Mode F:M
Lamivudine-zidovudine 331 51.6 261 300 0.9 1.4:1 35.6
Lopinavir-ritonavir 231 36.0 735 800 0.9 1:2.2 31.5
Efavirenz 157 24.5 807 600 0.9 1:3.6 38.4
Raltegravir 136 21.2 902 800 1.1 1:3.6 47.9
Darunavir 94 14.7 1125 1200 0.9 1:3.3 47.8
Tenofovir-emtricitabine 88 13.6 330 300 1.3 1:3.3 44.5
Etravirine 65 10.1 435 400 1.1 1:5.6 49.6
Abacavir-lamivudine 57 8.9 453 600 0.6 1:1.5 35.8
Ritonavir 37 5.8 154 200 0.1 1:3.4 50.9
Lamivudine 35 5.5 261 300 0.9 1:1.4 35.6
a Relation between the mean dosage and the defined daily dose (DDD)
Antiretroviral combinations n %
Lamivudine-zidovudine and            
lopinavir-ritonavir
189 29.5
Lamivudine-zidovudine and efavirenz 105 16.2
Raltegravir, etravirine and darunavir 44 6.9
Raltegravir and tenofovir-emtricitabine 29 4.5
Efavirenz-tenofovir-emtricitabine 29 4.5
Other 75 different combinations 245 38.4
five, 5 (0.8%) receiving six, and 2 (0.3%) receiving 
seven of these medications. The most frequently 
used regimens are shown in table 2, which 
shows the regimens used in 61.6% of the cases. 
The combination of lamivudine-zidovudine plus 
lopinavir-ritonavir represented almost one-third of 
the prescribed regimens. Importantly, 80 different 
combinations of antiretroviral drugs were found.
The multivariate analysis of the relationship 
between the use of four or more antiretrovirals 
and other variables showed that the variable 
age between 45 and 64 years (OR=2.25; 95% 
CI: 1.367-3.713; p=0.001) was the only variable 
significantly associated with a greater possibility of 
being treated with more medications.
Comedication
HIV infection is frequently accompanied by other 
pathologies that require treatment. Of the total 
subjects included, 267 (41.7%) received at least 
one comedication (1 to 18 additional drugs). The 
most frequently found included anti-ulcer drugs 
(n=153; 57.3%), lipid-lowering drugs (n=77; 28.8%), 
anti-hypertension drugs and diuretics (n=76; 
28,5%), antibiotics (n=59; 22.1%), antifungals 
(n=56; 21.0%), anti-depressants (n=39; 14.6%), 
anti-psychotics (n=36; 13.5%), anxiolytics and 
hypnotics (n=24; 9.0%) and anti-diabetics (n=21; 
7.9%).
The multivariate analysis showed that an age older 
than 65 years, the use of maraviroc, and receiving 
treatment in the city of Bogotá were significantly 
associated with a higher probability of receiving at 
least one comedication. Conversely, the variable 
age between 1 and 17 years was associated with a 
lower risk of receiving another group of medication 
(table 3).
Comparison among cities
The demographic variables and some indicators 
of prescription were also compared among the 28 
Colombian cities included in this study; however, 
for reasons related to the low number of patients 
in some of these cities, table 4 includes only the 
seven cities with the highest number of cases, 
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Table 3. Variables associated with antiretroviral treatment with comedication in binary logistic regression models, Colombia, 2015
Variables
Ba EEb Wald GLc Sigd ORe
95% CIf
Upper Lower
Age 1-17 years -1.013 0.414 5.994 1 0.014 0.363 0.162 0.817
Age >65 years 1.887 0.532 12.588 1 <0.001 6.599 2.327 18.715
Use maraviroc 2.392 1.081 4.899 1 0.027 10.931 1.315 90.882
Be treated in Bogotá 0.657 0.227 8.376 1 0.004 1.928 1.236 3.008
which encompasses 68.2% of the patients. The 
analysis was performed as described for the total 
patients in the country as a whole.
Discussion
This study enabled us to determine the antiretroviral 
drug prescription patterns most frequently used 
in patients affiliated with the Health System of 
Colombia. The information can be used by health 
administrators for decision making directed towards 
improving the treatment of HIV/AIDS patients. It is 
important to highlight that the vast majority of the 
medications analyzed in this study are included in 
the list of essential medications. Therefore, they 
have elevated intrinsic value and are considered the 
pharmacological groups of choice in antiretroviral 
therapy. Thus, these medications are deemed 
sufficient for managing HIV/AIDS.
The results of this study were similar to other 
studies regarding the age and gender of HIV/AIDS 
patients. A total of 93.3% of the patients were older 
than 15 years, with a slightly higher prevalence of 
men with this pathology. This result shows that the 
Table 4. Comparison of some demographic variables and indicators of antiretroviral prescriptions among seven Colombian cities, 
2015
Bogotá Cali Medellín Armenia Pereira Barranquilla Manizales Colombia
(n=158) (n=104) (n=74) (n=28) (n=26) (n=26) (n=21) (n=641)
Mean age (years) 33.7 46.3 39.4 44.6 44 37.6 34.7 38.9
Men (%) 68.4 68.3 40.5 35.7 46.1 80.8 52.3 60.2
Sex ratio F:M 1:2.2 1:2.2 1.5:1 1.8:1 1.4:1 1:4.2 1:1.1 1:1.5
Prescription rate (%)
Lamivudine-zidovudine and 
lopinavir-ritonavir
17.7 22.1 48.6 67.8 42.3 19.2 52.3 29.5
Lamivudine-zidovudine and 
efavirenz
13.9 5.8 0 7.1 7.7 3.8 0 16.2
Raltegravir,etravirine and 
darunavir
3.8 7.7 8.1 7.1 15.4 0 23.8 6.9
Raltegravir and            
tenofovir-emtricitabine
4.4 10.6 8.1 3.7 0 7.7 0 4.5
Efavirenz-                     
tenofovir-emtricitabine
12 4.8 2.7 0 3.8 11.5 0 4.5
a Regression coefficient, b Standard error, c Level of freedom, d Significance level, e Odds ratio, f Confidence interval of 95%
gender gap that previously existed and that favored 
women with a lower frequency has been closing 
(3). 
We found that the most prescribed antiretroviral 
medications were NRTIs, followed by PIs and 
NNRTIs. This situation is not surprising given 
the broad recommendation of regimens based 
on NRTIs (13). Nevertheless, the combination of 
lamivudine-zidovudine as the most formulated drug 
should be revised. Currently, zidovudine is not one 
of the drugs recommended as a first-line medication 
in ART due to its adverse effects (i.e., marrow 
suppression, lipodystrophy and lactic acidosis) and 
dosing type (13,14). In contrast, scientific evidence 
supports the use of first-line regimens based on 
tenofovir and abacavir-lamivudine (13,14). Among 
the PIs, the use of lopinavir-ritonavir as the second 
most commonly used drug (36.0%) entails a high 
pill burden (the number of capsules or other dosage 
forms that a person takes on a regular basis), risk 
of metabolic changes, and low tolerability; thus, it 
is not the preferred PI (7). Regarding the NNRTIs, 
the use of efavirenz is considered adequate given 
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its long-term efficacy and safety (13). The use of 
integrase inhibitors, coreceptor CCR5 antagonists, 
and fusion inhibitors is also important but has not 
been reported in previous studies due to their 
relatively recent appearance in HIV management 
(7).
A total of 103 (16.1%) patients used four or more 
antiretrovirals, probably due to a failure of the initial 
ART. This condition is frequently associated with 
a lack of adherence to treatment and can be tied 
to the presentation of the adverse effects of these 
medications, the length of time the patient has had 
the infection, the exacerbation of comorbidities, the 
interactions with other drugs, the daily pill burden, 
and the frequency of dosing (13).
When reviewing the profiles, it was immensely 
surprising to find 80 different combinations of 
antiretroviral drugs. This finding may indicate 
that the diversity of prescriptions is due to a lack 
of adequate criteria for the implementation of 
regimens in accordance with scientific information 
and that the prescribers adopt multiple options that 
are beyond the recommendations made worldwide 
(11,12).
Ritonavir has definitively positioned itself as a 
booster drug by inhibiting the metabolism of the 
different PIs and elevating their concentrations. 
This condition of use can be observed in this 
study because ritonavir is prescribed at the dose 
indicated for this purpose (7). In the case of the 
lower dose of abacavir-lamivudine, the causes 
should be identified because it could also be due to 
an improper use of the drug (15). 
We found that peptic acid disease, dyslipidemias, 
and arterial hypertension were the most prevalent 
diseases, which was similar to the reports of other 
studies (7,16). 
The large number of patients with comedications 
for the treatment of non-communicable chronic 
diseases is striking; this situation reminds us 
of the transformation of HIV into a chronic and 
treatable disease and has implications for systemic 
repercussions in the treatment processes (6,17). 
It is important to highlight the possible medication 
interactions between antiretrovirals and the drugs 
used for the treatment of other pathologies, 
especially with some anti-hypertensives of the 
calcium channel antagonist type wholesale 
reduction of blood pressure, and with lipid-lowering 
drugs, such as lovastatin and simvastatin by an 
increased risk of myopathies (18). 
The finding that patients older than 65 years 
more frequently received other medications for 
the management of comorbidities is a common 
condition for subjects at this age, who usually suffer 
from other chronic non-communicable morbidities 
that require specific management that may have 
medication interactions with antiretrovirals (19-22). 
The association found between the use of maraviroc 
and the greater risk of receiving comedications 
may be related to treating patients who have been 
undergoing treatment for HIV for a longer time, 
are older and require an effective medication after 
having experienced some therapeutic failure (23).
The limitations of this study are that the data were 
obtained from a database and not from the patients’ 
clinical histories and that the study subjects 
were affiliated only with the contributive system; 
therefore, the results could be extrapolated only to 
individuals with similar insurance characteristics. 
Additionally, no information on the diagnosis of the 
comorbidities was included. However, the study 
does have strengths, such as the rigor in obtaining 
the data and the use of a reliable population 
database.
The ART recommendations have constantly 
evolved since the very beginning. Currently, 
treatment is oriented towards the use of effective 
but less toxic drugs that have simpler dosing. In 
relation to this premise, the results in the present 
study suggest that the large number of regimens 
being used should be reviewed, including some that 
currently are not considered first-line in ART. This 
finding is important because a patient’s adherence 
is improved by a lower presentation of adverse 
effects and greater comfort with the treatment, 
which is without a doubt a fundamental condition 
for the success of therapy.
We can conclude that the patients on ART are 
receiving medications with increased intrinsic value 
or high therapeutic utility at the recommended 
doses and are presenting the same comorbidities 
associated with chronic age-related conditions. 
However, they are also being treated with a great 
variety of regimens that are not included in the 
clinical practice guidelines for the management of 
HIV/AIDS in the country or internationally. Rational 
prescription habits should be fostered with the 
use of medications with high therapeutic value at 
the defined doses in combinations with sufficient 
scientific support.
The information found in this study may be useful 
for administrators of health systems and services 
in decision making on how their doctors are 
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treating this group of patients and to improve the 
quality of the treatment of programs for HIV/AIDS 
management with the aim of reducing resistance to 
medications.
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